Skip to main content

Peer Review reports

From: Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma

Original Submission
30 Mar 2021 Submitted Original manuscript
Resubmission - Version 2
Submitted Manuscript version 2
2 May 2021 Reviewed Reviewer Report - Alexandr Poprach
3 May 2021 Reviewed Reviewer Report
11 Jun 2021 Author responded Author comments - Thomas Powles
Resubmission - Version 3
11 Jun 2021 Submitted Manuscript version 3
23 Jun 2021 Reviewed Reviewer Report
Resubmission - Version 4
Submitted Manuscript version 4
Publishing
16 Jul 2021 Editorially accepted
7 Aug 2021 Article published 10.1186/s12885-021-08630-w

You can find further information about peer review here.

Back to article page